Abstract 1463P
Background
Chemotherapy in combination with anti-PD-1/PD-L1 antibodies (chemoimmunotherapy) has become the standard treatment for advanced non-small cell lung cancer (NSCLC). Our previous studies highlighted that low baseline concentrations of IL-6 in plasma specimens or tumor tissues responded better to anti-PD-1/PD-L1 immunotherapy alone. However, the role of baseline IL-6 levels in predicting responses to chemoimmunotherapy and the development of resistance to chemoimmunotherapy has not been fully understood yet.
Methods
To confirm the predictive value of IL-6 in the baseline plasma, we conducted an enzyme-linked immunosorbent assay (ELISA) in a group of 123 advanced NSCLC patients who received chemoimmunotherapy. Next, we evaluated the role of IL-6 in chemoimmunotherapy resistance and the underlying mechanisms in mouse models of both lung adenocarcinoma and lung squamous cell carcinoma.
Results
Based on our cohort of 123 NSCLC patients, we found that patients with progressive disease had a higher baseline level of IL-6 in their plasma. Additionally, the potential predictive value of the baseline level of IL-6 in plasma samples for responses was confirmed with area under curve (AUC) up to 0.677. Patients with a low baseline concentration of IL-6 also had a longer progression-free survival and overall survival, with a cut-off value of 7.002 obtained from receiver operating characteristic curve (ROC). Meanwhile, univariate and multivariate Cox regression analyses revealed that baseline IL-6 level in plasma samples was an independent prognostic predictor. Further experiments in mouse models showed that overexpression of IL-6 weakened the anti-tumor effects of immunotherapy in combination with chemotherapy. Immunohistochemical studies also revealed that CD8+ T cells decreased while M2 macrophages, regulating T cells, and myeloid-derived suppressor cells infiltration increased in the IL-6 overexpressing group.
Conclusions
Our study highlights the potential of baseline IL-6 levels as a useful predictive biomarker for chemoimmunotherapy in NSCLC. IL-6 promotes an immunosuppressive tumor microenvironment, suggesting that targeting IL-6 could be a promising approach for cancer treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1422P - Comprehensive genomic profiling (CGP) changes management and improves survival in patients with advanced non-small cell lung cancer (aNSCLC)
Presenter: George Simon
Session: Poster session 20
1423P - Clinical impact of radiological diagnosis of lymphangitic carcinomatosis in patients with extensive non-small cell lung cancer treated with immunotherapy
Presenter: Anita Bolina
Session: Poster session 20
1424P - Outcome of thromboembolic events and its influence on survival time of advanced NSCLC patients receiving antiangiogenic therapy
Presenter: Wei-Fan Ou
Session: Poster session 20
1425P - Clinical utility of liquid biopsy for the early diagnosis of EGFR mutant advanced lung cancer in real-life setting (CLEAR)
Presenter: Rola El Sayed
Session: Poster session 20
1427P - Exploration of the value of leptomeningeal biopsy in diagnosing and treating non-small cell lung cancer with leptomeningeal metastasis
Presenter: Lin Cai
Session: Poster session 20
1428P - Clinical benefit of combination chemo-immunotherapy in first-line treatment for patients over the age of 65 or 75 with metastatic NSCLC
Presenter: Thierry Landre
Session: Poster session 20
1429P - Homologous recombination repair (HRR) gene mutation: A novel biomarker for precision genomics testing in advanced lung cancer
Presenter: Madhu Nagaraj
Session: Poster session 20
1430P - Excellent performance of a fast and fully-automated RNA based genefusion assay conducted on a large fusion positive non-small cell lung cancer cohort within a multicenter study
Presenter: Arndt Hartmann
Session: Poster session 20
1431P - The nNGM Preclinical Platform: Preclinical research to generate evidence for patients with non-small cell lung cancer harboring variants of unknown significance
Presenter: Martin Ziegler
Session: Poster session 20